[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Science and Technology Council, Taiwan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":85},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,63],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100628467",false,"NCT07462013","Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice","Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice (POWER)","POWER","Inclusion Criteria:\n\n* Aged 50-80 years old\n* Major Depressive Disorder\n* Absence or mild cognitive impairment\n\nExclusion Criteria:\n\n\\-","ALL","50 Years","80 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","POWER project is a randomized, controlled, non-profit study with the primary objective of testing the effectiveness of non-pharmacological interventions-such as physical activity, cognitive training, and dietary supplementation-in reducing depressive symptoms and preventing or delaying cognitive impairments that frequently co-occur in individuals with Major Depressive Disorder (MDD).",[27],"Major Depressive Disorder (MDD)","RECRUITING","2026-06-15",{"date":31,"type":32},"2026-06-17","ACTUAL",{"date":34,"type":32},"2025-10-01",{"date":36,"type":21},"2028-09",{"name":38,"class":39},"National Science and Technology Council, Taiwan","OTHER_GOV",1,{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100631441","NCT07500714","Integrating Digital Phenotypes and AI-Driven Cognitive-Behavioral Therapy: Advancing Precision Medicine in Depression Through Digital Medicine","Inclusion Criteria:\n\n* (1) Aged 18-75 years\n* Diagnosis of major depressive disorder disorder (Based on Diagnostic Statistical Manual 5)\n* 21-item Hamilton Depression Scale (HAMD21)\\>17\n* No changes in current psychiatric treatment for depression (e.g., no treatment, antidepressant medication, psychotherapy, or non-invasive brain stimulation) within the past four weeks, and\n* Full competency to understand the study details and provide written informed consent\n\nExclusion Criteria:\n\n* Scores of 5 ( Markedly ill), 6,(Severely ill), and 7 (Among the most extremely ill) according to the Clinical Global Impression Scale-Severity (CGI-S)\n* Psychotic disorders, bipolar affective disorder, a substance use disorders in the past 6 months, active suicidal or homicidal ideation (per assessment or HAMD\\>3)\n* Unstable or active medical illness.",true,"18 Years","75 Years",{"count":50,"type":21},100,[24],"This project aims to integrate digital phenotyping and AI-driven iCBT into a comprehensive platform for MDD diagnosis and treatment in Taiwan. The study will explore dynamic, real-time behavioral and physiological markers to refine diagnostic classifications and optimize personalized therapeutic strategies.",[54],"Depression - Major Depressive Disorder","2026-03-25",{"date":57,"type":32},"2026-03-30",{"date":59,"type":32},"2025-06-01",{"date":61,"type":21},"2027-07",{"name":38,"class":39},{"id":64,"slug":4,"hasResults":10,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":10,"sex":16,"minAge":47,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":40},"100626754","NCT07439744","NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status","Effects of 12-week n-3 PUFA Treatment (EPA) on Depressive Symptoms in Overweight\u002FObese Depressed Subjects With Low n-3 PUFA Status: Relationship With Systemic Inflammation","Inclusion Criteria:\n\n* Major depressive disorder.\n* Antidepressant drug-free.\n\nExclusion Criteria:\n\n* Schizophrenia\n* Mania\n* Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)\n* Obsessive-compulsive disorder\n* Post-traumatic stress disorder\n* Alcohol or drug abuse\u002Fdependence (except for nicotine)\n* Active suicidal ideation\n* Serious medical\u002Fneurological conditions, especially requiring corticosteroid\u002Fnon-steroidal anti-inflammatory or immunosuppressive therapies or chronic thyroid hormone replacement","54 Years",{"count":71,"type":21},50,[24],"A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g\u002Fday) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \\\u003C 8%) (81), from the Taiwanese cohort. Associations with PLA2\u002FCOX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.",[75,76],"Obese Adults","MDD","2026-02-23",{"date":79,"type":32},"2026-02-27",{"date":81,"type":32},"2025-03-01",{"date":83,"type":21},"2027-12",{"name":38,"class":39},""]